# To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension

> **NCT02047656** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 93 (actual)

## Conditions studied

- Part 1 - Healthy Volunteers
- Part 2 - Patients With Hypertension

## Interventions

- **DRUG:** LFF269
- **DRUG:** Placebo to LFF269

## Key facts

- **NCT ID:** NCT02047656
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-08
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2016-04-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02047656

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02047656, "To Evaluate Pharmacokinetics of LFF269 in Healthy Volunteers and Patients With Hypertension". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02047656. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*